Magnolia Medical Technologies aims to eliminate in-vitro diagnostic errors in healthcare institutions. Their evidence-based technology platform, Steripath, prevents contamination leading to misdiagnosis of bloodstream infections, including sepsis, and false-positive CLABSIs. They have an extensive intellectual property portfolio consisting of over 100 issued patents and 70+ patent applications pending. Their mission is to improve patient outcomes and reduce system-wide costs associated with diagnostic errors.